Value of novel agents and intensive therapy for patients with multiple myeloma

R. Alexanian; M. Wang; K. Delasalle; S. Wang; M. Qazilbash; B. Handy; D. Weber

doi:10.1038/bmt.2013.189

Value of novel agents and intensive therapy for patients with multiple myeloma

R. Alexanian, M. Wang, K. Delasalle, S. Wang, M. Qazilbash, B. Handy, D. Weber

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide-or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year. Survival times were calculated after a landmark of 1 year from start of therapy, so that subsequent median survival was 8.9 years for patients with CR, 4.9 years for those with PR and 0.6 year for patients with NR (P<0.001). Multivariate analyses confirmed CR or PR as the major favorable factors with less impact on prognosis for age or disease stage. Both novel agents and high-dose therapy (HDT) resulted in high frequencies of PR or CR, with early HDT useful for many patients with NR or PR in improving response status and subsequent survival.

Original language	English (US)
Pages (from-to)	422-425
Number of pages	4
Journal	Bone marrow transplantation
Volume	49
Issue number	3
DOIs	https://doi.org/10.1038/bmt.2013.189
State	Published - Mar 2014

Keywords

auto-SCT
multiple myeloma
prognostic factors

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/bmt.2013.189

Cite this

@article{aef058436b774bfcb2d41ab2ddaaff0f,

title = "Value of novel agents and intensive therapy for patients with multiple myeloma",

abstract = "We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide-or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year. Survival times were calculated after a landmark of 1 year from start of therapy, so that subsequent median survival was 8.9 years for patients with CR, 4.9 years for those with PR and 0.6 year for patients with NR (P<0.001). Multivariate analyses confirmed CR or PR as the major favorable factors with less impact on prognosis for age or disease stage. Both novel agents and high-dose therapy (HDT) resulted in high frequencies of PR or CR, with early HDT useful for many patients with NR or PR in improving response status and subsequent survival.",

keywords = "auto-SCT, multiple myeloma, prognostic factors",

author = "R. Alexanian and M. Wang and K. Delasalle and S. Wang and M. Qazilbash and B. Handy and D. Weber",

year = "2014",

month = mar,

doi = "10.1038/bmt.2013.189",

language = "English (US)",

volume = "49",

pages = "422--425",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Value of novel agents and intensive therapy for patients with multiple myeloma

AU - Alexanian, R.

AU - Wang, M.

AU - Delasalle, K.

AU - Wang, S.

AU - Qazilbash, M.

AU - Handy, B.

AU - Weber, D.

PY - 2014/3

Y1 - 2014/3

N2 - We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide-or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year. Survival times were calculated after a landmark of 1 year from start of therapy, so that subsequent median survival was 8.9 years for patients with CR, 4.9 years for those with PR and 0.6 year for patients with NR (P<0.001). Multivariate analyses confirmed CR or PR as the major favorable factors with less impact on prognosis for age or disease stage. Both novel agents and high-dose therapy (HDT) resulted in high frequencies of PR or CR, with early HDT useful for many patients with NR or PR in improving response status and subsequent survival.

AB - We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide-or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year. Survival times were calculated after a landmark of 1 year from start of therapy, so that subsequent median survival was 8.9 years for patients with CR, 4.9 years for those with PR and 0.6 year for patients with NR (P<0.001). Multivariate analyses confirmed CR or PR as the major favorable factors with less impact on prognosis for age or disease stage. Both novel agents and high-dose therapy (HDT) resulted in high frequencies of PR or CR, with early HDT useful for many patients with NR or PR in improving response status and subsequent survival.

KW - auto-SCT

KW - multiple myeloma

KW - prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=84904242532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904242532&partnerID=8YFLogxK

U2 - 10.1038/bmt.2013.189

DO - 10.1038/bmt.2013.189

M3 - Article

C2 - 24317125

AN - SCOPUS:84904242532

SN - 0268-3369

VL - 49

SP - 422

EP - 425

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 3

ER -

Value of novel agents and intensive therapy for patients with multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this